Evidence map›Paper›PMID 38317634›Full record

ArticleJournal of comparative effectiveness research2024

Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.

Emmanouil Sinakos, Nandita Kachru, Christos Tsoulas, Sushanth Jeyakumar, Nathaniel J Smith, Alon Yehoshua, Evangelos Cholongitas

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Emmanouil Sinakos4th Department of Internal Medicine, Hippokratio Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Nandita KachruGilead Sciences Inc., Foster City, CA 94404, USA.
Christos TsoulasGilead Sciences Inc., Foster City, CA 94404, USA.
Sushanth JeyakumarMaple Health Group, LLC, New York, NY 10019, USA.
Nathaniel J SmithMaple Health Group, LLC, New York, NY 10019, USA.
Alon YehoshuaGilead Sciences Inc., Foster City, CA 94404, USA.
Evangelos CholongitasFirst Department of Internal Medicine, Medical School of National & Kapodistrian University of Athens, Athens, Greece.
Gilead Sciences (United States) · USAristotle University of Thessaloniki · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hepatitis B, ChronicLiver NeoplasmsAdenineAntiviral AgentsCost-Benefit AnalysisGreeceGuanineHumansLiver CirrhosisTenofovirTreatment OutcomeAdenineAntiviral AgentsentecavirGuanineTenofovircost–effectivenessentecavirhepatitis Btenofovir alafenamidetenofovir disoproxil fumarate

Identifiers

PMID38317634
PMCPMC11044955
OpenAlexW4391574826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.